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Abstract
Toxicometabolomics, essentially applying metabolomics to toxicology of endogenous compounds such as drugs of abuse 
or new psychoactive substances (NPS), can be investigated by using different in vitro models and dedicated metabolomics 
techniques to enhance the number of relevant findings. The present study aimed to study the toxicometabolomics of the 
two NPS α-pyrrolidinobutiophenone (1-phenyl-2-(pyrrolidin-1-yl)butan-1-one, α-PBP) and α-pyrrolidinoheptaphenone 
(1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one, α-PEP, PV8) in HepaRG cell line incubates. Evaluation was performed using 
reversed-phase and normal-phase liquid chromatography coupled with high-resolution mass spectrometry in positive and 
negative ionization mode, respectively, to analyze cells and cell media. Statistical evaluation was performed using one-way 
ANOVA, principal component discriminant function analysis, as well as hierarchical clustering. In general, the analysis 
of cells did not mainly reveal any features, but the parent compounds of the drugs of abuse. For α-PBP an increase in 
N-methylnicotinamide was found, which may indicate hepatotoxic potential of the substance. After analysis of cell media, 
significant features led to the identification of several metabolites of both compounds. Amino acid adducts with glycine and 
alanine were found, and these have not been described in any study before and are likely to appear in vivo. Additionally, 
significant changes in the metabolism of cholesterol were revealed after incubation with α-PEP. In summary, the applica-
tion of metabolomics techniques after HepaRG cells exposure to NPS did not lead to an increased number of identified 
drug metabolites compared to previously published studies, but gave a wider perspective on the physiological effect of the 
investigated compounds on human liver cells.
Keywords Toxicometabolomics · HepaRG · Untargeted metabolomics · HPLC–HRMS/MS · New psychoactive substances
Introduction
Several in vitro models have been developed and used for 
investigating the metabolism of drugs of abuse (DOA) and 
new psychoactive substances (NPS), and also for xenobiotics 
in general (Manier et al. 2018; Richter et al. 2017a, b; Sinz 
2012; Sinz and Kim 2006). They are based on subcellular 
fractions such as pooled human liver microsomes (pHLM), 
pooled human liver cytosol, or pooled human liver S9 frac-
tion (pHLS9), as well as hepatic cell lines such as HepG2 
and HepaRG. Additionally, primary cells can be used after 
isolation from tissue by enzymatic digestion or mechani-
cal force (Sinz and Kim 2006). Primary human hepatocytes 
are regarded as the most suitable in vitro model predict 
in vivo metabolism, since a high number of reactions can 
be observed such as those catalyzed by cytochrome P450 
(CYP) enzymes and by flavin-containing monooxygenases 
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(FMOs), as well as conjugation with glucuronic acid, sulfate, 
and glutathione (Sinz and Lyubimov 2011). In subcellular 
fractions, only some of these reactions can be observed. 
For instance, pHLM are limited to reactions catalyzed by 
membrane-bound enzymes such as CYP enzymes, FMOs, 
and uridine 5′-diphospho-glucuronosyltransferases (UGTs). 
Since these reactions are the most relevant ones in drug 
metabolism, pHLM are widely applied in such studies (Sinz 
and Lyubimov 2011). Due to their limitations, pHLM still 
might fail to predict in vivo excretion products, particularly 
those that were subject to phase II metabolism other than 
glucuronidation or a combination of both phase I and II 
metabolism. In pHLS9, an unseparated mixture of cytosol 
and microsomes, both phase I and phase II metabolites, are 
present, but it generally suffers from lower enzyme activi-
ties compared to isolated fractions (Brandon et al. 2003; 
Zhang et al. 2012). Immortalized cell lines such as HepaRG 
and HepG2 are often applied to avoid the high costs of pri-
mary human hepatocytes and to apply a model that is better 
suited to represent the physiology of liver cells (Sinz and 
Kim 2006).
Metabolomics studies are dedicated to investigate the 
change of all detectable small molecules in a biological sys-
tem on a global or network scale (Liu and Locasale 2017). 
This includes in silico methods such as automated peak 
detection and integration, as well as methods from uni- and 
multivariate statistics to evaluate the results and obtain an 
impartial image of the changes (Barnes et al. 2016a; Liu and 
Locasale 2017; Worley and Powers 2013). Metabolomics 
techniques are applied to investigate the response to patho-
physiological stimuli or genetic modifications (Lindon et al. 
2000) such as cancer (Dang et al. 2009), diseases (Wild et al. 
2019), or intoxications (D’Elia et al. 2019). Metabolomics 
has lately also been used to study DOA or NPS, either with a 
focus on the drug metabolism (Manier et al. 2019a; Mortele 
et al. 2018; Vervliet et al. 2019a) or the wider changes of the 
metabolome in abusers (Boxler et al. 2018). The huge poten-
tial of these techniques for the identification of biomarkers of 
DOA or NPS abuse can be found in the enhanced number of 
metabolites that might be detected and the identification of 
compounds that at first do not seem to be related to the drug 
(Manier et al. 2019a; Vervliet et al. 2019b). However, the 
toxicometabolomics, which means applying metabolomics 
to toxicology (Manier and Meyer 2020; Milburn et al. 2013), 
of DOA/NPS in HepaRG cells by means of metabolomics 
techniques has not been investigated yet. As such lines offer 
a comparable standardized biological environment, a high 
similarity to the actual physiology of the liver, and metabo-
lites comparable to that of the microsomal fractions (Richter 
et al. 2017a), this approach appears to be promising.
The aims of study were therefore to investigate the toxi-
cometabolomics of the two NPS α-pyrrolidinobutiophenone 
(1-phenyl-2-(pyrrolidin-1-yl)butan-1-one, α-PBP) and 
α-pyrrolidinoheptaphenone (1-phenyl-2-(pyrrolidin-1-yl)
heptan-1-one, α-PEP, PV8) in HepaRG incubations. Pyr-
rolidinophenone-derived NPS are synthetic derivatives of 
the natural alkaloid cathinone. The primary amine moiety 
within the cathinone molecule is replaced by a pyrrolidine 
ring and the α-carbon is substituted with alkyl chains of dif-
ferent lengths. Consumption and seizure of these stimulants 
has been reported in Europe as well as Japan (EMCDDA 
2015; Kudo et al. 2015; Odoardi et al. 2016; Swortwood 
et al. 2016). The general metabolism of the two NPS in, 
e.g., pHLM has so far been investigated (Manier et al. 2018, 
2019a; Matsuta et al. 2015; Swortwood et al. 2016). The 
results shall be compared with those studies.
Materials and methods
Chemicals and reagents
α-PBP and α-PEP were provided by the Bavarian State 
Criminal Police Office (Munich, Germany). Water was puri-
fied with a Millipore filtration unit (which purifies water to 
a resistance of 18.2 Ω × cm). Cryopreserved, differentiated 
HepaRG cells, 96-well plates coated with type I collagen, 
fetal bovine serum, Williams’ E Medium, GlutaMAX, sup-
plement HPRG620, and supplement HPRG670 were from 
Life Invitrogen (Darmstadt, Germany). Penicillin and strep-
tomycin were purchased from Sigma-Aldrich (Taufkirchen, 
Germany), tryptophan-d5 was purchased from Alsachim 
(Illkirch Graffenstaden, France), acetonitrile (LC–MS 
grade), ammonium formate (analytical grade), formic acid 
(LC–MS grade), methanol (LC–MS grade), and all other 
chemicals and reagents (analytical grade) were from VWR 
(Darmstadt, Germany). Reaction tubes and pipette tips were 
obtained from Sarstedt (Nümbrecht, Germany).
Incubations using HepaRG cells
Incubations using HepaRG cells were performed accord-
ing to a previous publication (Richter et al. 2019). For each 
experiment, cells were maintained in an incubator (Binder, 
Tuttlingen, Germany) at 37 °C with 95% air humidity and 
5%  CO2 atmosphere. Cell handling was done under sterile 
conditions using a laminar flow bench class II (Thermo Sci-
entific Schwerte, Germany). All given concentrations are 
final concentrations. Cryopreserved, differentiated Hep-
aRG cells were cultivated according to the manufacturer’s 
instructions and seeded in a density of 80,000 cells/well in 
collagen-coated 96-well plates using Williams’ E medium 
supplemented with 1% GlutaMAX, HPRG670, 100 U/mL 
penicillin, 100 µg/mL streptomycin, and 0.5% DMSO on 
day 1. On day 2, this medium was replaced by the above 
described medium containing HPRG620 instead of ADD670 
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and subsequently renewed on day 5. On day 8, α-PBP and 
α-PEP were freshly dissolved in DMSO and subsequently 
diluted using the medium to the required concentration. The 
cell medium was finally renewed and additionally contained 
either 0 (group Blank), 12.5 (group Low) or 25 µM (group 
High) α-PBP or α-PEP, respectively. Each concentration was 
used in nine different wells. Medium volume was always 
100 µL. After 24 h of exposure, the medium was transferred 
into a second 96-well plate that was not collagen coated. 
The cells were washed twice using 100 µL of phosphate-
buffered saline (PBS buffer). Both plates were shock frosted 
using liquid nitrogen and subsequently stored at − 80 °C 
until analysis.
Metabolomics sample preparation
After 3 days at − 80 °C, the cells were extracted (extract 
1) on dry ice using a modified extraction method and rec-
ommendations published previously (Barnes et al. 2016b; 
Van den Eede et al. 2015). For this purpose, 100 µL of a 
precooled (− 80 °C) extraction mixture containing metha-
nol and purified water (8:2, v/v) and 5 µM tryptophan-d5 as 
internal standard was added to the cells. The mixture was 
incubated for 15 min on dry ice until the content of each 
well was transferred into a reaction tube. This procedure was 
repeated once and both aliquots of each well were combined. 
All samples were shaken for 2 min at 2000 rpm and subse-
quently centrifuged for 30 min at 15,000 rpm and 2 °C. 150 
µL of the supernatant was transferred into a new reaction 
tube and evaporated to dryness using a vacuum centrifuge 
(Concentrator plus, Eppendorf, Hamburg) at room tempera-
ture and program “V-aq” for roughly 1 h. The residue was 
reconstituted in 50 µL of a mixture containing methanol and 
acetonitrile (3:7, v/v) by shaking for 5 min at 15,000 rpm 
and 22 °C. Ten µL of each sample of both drugs of abuse 
were pooled to obtain one quality control sample (group QC) 
for every cell experiment.
For cell media extraction (extract 2), 70 µL of each of the 
cell media samples was transferred into a reaction tube and 
mixed with 210 µL precooled methanol (− 80 °C) containing 
5 µM tryptophan-d5 by shaking for 2 min at 2000 rpm. 200 
µL of each supernatant was transferred into a new reaction 
tube and evaporated to dryness under the above described 
conditions for roughly 2.5 h. Again, the residues were recon-
stituted in 50 µL of a mixture containing methanol and ace-
tonitrile (3:7, v/v) by shaking for 5 min at 15,000 rpm and 
22 °C. Ten µL of each sample of both drugs was pooled to 
obtain quality control samples (group QC) for every medium 
experiment.
Every obtained sample was transferred into an amber 
glass vial and 1 µL was injected onto the HPLC–HRMS/
MS as described in the corresponding paragraph.
Incubation and sample preparation 
for investigation of imine formation
To confirm the formation of imines by α-PBP and α-PEP 
when being incubated with glycine, several conditions were 
chosen based on previous studies (Welter et al. 2013). Gly-
cine concentration was based on its concentration in the 
Williams’ E medium. α-PBP and α-PEP were freshly dis-
solved and subsequently diluted using either purified water, 
Williams’ E medium, or Tris buffer to obtain the required 
concentrations prior to the experiment. The same was done 
for glycine, except for the dilution in Williams’ E medium. 
Incubations were conducted at 37 °C for 24 h using 25 µM 
α-PBP or α-PEP in either Tris buffer containing 0 or 666 µM 
glycine, Williams’ E medium, or purified water containing 
0 or 666 µM glycine. Additionally, all incubations were per-
formed without α-PBP and α-PEP containing 0 or 666 µM 
glycine. Incubation volume was 50 µL, respectively. Each 
experiment was performed in triplicate. After incubation, 
10 µL of 25% formic acid in purified water was added to the 
samples, as well as 40 µL of Eluent F as described in the fol-
lowing paragraph to obtain pH 3 in all samples. A 10-µL ali-
quot was subsequently injected onto the HPLC–HRMS/MS.
LC–HRMS/MS apparatus
The analysis was performed using a Thermo Fisher Scien-
tific (TF, Dreieich, Germany) Dionex UltiMate 3000 RS 
pump consisting of a degasser, a quaternary pump, and an 
UltiMate Autosampler, coupled to a TF Q-Exactive Plus sys-
tem equipped with a heated electrospray ionization HESI-II 
source. Mass calibration was done prior to analysis accord-
ing to the manufacturer’s recommendations using external 
mass calibration. Additionally before each experiment, the 
spray shield and capillary were cleaned. The performance 
of the column and the mass spectrometer was tested using 
a mixture as described by Maurer et al. (2016, 2018) prior 
to every experiment. The conditions were set according to 
published procedures (Helfer et al. 2015; Wagmann et al. 
2017). Gradient reversed-phase elution was performed on 
a TF Accucore PhenylHexyl column (100 mm × 2.1 mm, 
2.6 µm, TF, Dreieich, Germany) or on a hydrophilic inter-
action liquid chromatography (HILIC) Nucleodur column 
(125 × 3 mm, 3 μm, Macherey–Nagel, Düren, Germany) for 
normal-phase chromatography. The mobile phases for gra-
dient elution using the PhenylHexyl column consisted of 
2 mM aqueous ammonium formate containing acetonitrile 
(1%, v/v) and formic acid (0.1%, v/v, pH 3, eluent A), as 
well as 2 mM ammonium formate in acetonitrile and metha-
nol (1:1, v/v), containing water (1%, v/v) and formic acid 
(0.1%, v/v, eluent B). The flow rate was set from 1–10 min 
to 500 µL/min and from 10–13.5 min to 800 µL/min using 
the following gradient: 0–1.0 min hold 99% A, 1–10 min to 
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1% A, 10–11.5 min hold 1% A, 11.5–13.5 min hold 99% A. 
Normal-phase chromatography was performed using aque-
ous ammonium acetate solution (200 mM, eluent C) and 
acetonitrile containing formic acid (0.1%, v/v, eluent D). For 
chromatography of imines, eluent C was replaced by aque-
ous ammonium formate solution (20 mM, eluent E) adjusted 
to pH 3 using formic acid and eluent D was replaced with a 
mixture of 200 mM aqueous ammonium formate and ace-
tonitrile (1:10, v/v, eluent F). These experiments were per-
formed on the HILIC column using the positive ionization 
mode. The flow rate was set to 500 µL/min using the follow-
ing gradient: 0–1 min 2% C, 1–5 min to 20% C, 5–8.5 min 
to 60% C, 8.5–10 min hold 60% C, 10–12 min hold 2% C. 
For preparation and cleaning of the injection system, a mix-
ture containing isopropanol and water (90:10, v/v) was used. 
The following settings were used: wash volume, 100 µL; 
wash speed, 4000 nL/s; loop wash factor, 2. Every analysis 
was performed at 40 °C column temperature, maintained 
by a Dionex UltiMate 3000 RS analytical column heater. 
The injection volume for metabolomics analyses was 1 µL 
and for those analyses investigating the formation of imines 
10 µL. The HESI-II source conditions for every experi-
ment were as follows: ionization mode, positive or nega-
tive; sheath gas, 60 AU; auxiliary gas, 10 AU; sweep gas, 
3 AU; spray voltage, 3.50 kV in positive mode and -4.0 kV 
in negative mode; heater temperature, 320 °C; ion transfer 
capillary temperature, 320 °C; and S-lens RF level, 50.0. 
Mass spectrometry for untargeted metabolomics (UM) was 
performed according to a previously optimized workflow 
using full scan (FS) only (Manier et al. 2019b). The settings 
for FS data acquisition were as follows: resolution, 140,000 
fwhm; microscans, 1; automatic gain control (AGC) target, 
5 ×  105; maximum injection time, 200 ms; scan range, m/z 
50–750; polarity, negative or positive; spectrum data type, 
centroid.
The settings for parallel reaction monitoring (PRM) data 
acquisition were as follows: resolution, 35,000 fwhm; micro-
scans, 1; AGC target, 5 ×  105; maximum injection time, 
200 ms; isolation window, 1.0 m/z; collision energy (CE), 
10, 20, or 40 eV; spectrum data type, centroid. The inclu-
sion list contained the monoisotopic masses of all signifi-
cant features and a time window of their retention time ± 
30 s. Analysis was performed using a randomized sequence 
order with five injections of pure methanol (reversed-phase 
chromatography) or eluent D (normal-phase chromatogra-
phy) samples at the beginning of the sequence for apparatus 
equilibration, followed by five injections of the pooled QC 
sample. Additionally, one QC injection was performed every 
five samples to monitor batch effects as described by Weh-
rens et al. (2016).
Analysis concerning additional incubations to confirm 
the formation of imines was performed using full scan (FS) 
data and subsequent data-dependent acquisition (DDA). The 
settings for FS data acquisition were as follows: resolution, 
35,000; microscans, 1; automatic gain control (AGC) tar-
get, 1e6; maximum injection time, 120 ms; and scan range, 
m/z 50–50. The settings for the DDA mode were as follows: 
dynamic exclusion, 0.1 s; resolution, 17,500; microscans, 
1; loop count, 5; AGC target, 2e4; maximum injection time, 
250 ms; isolation window, m/z 1.0; high collision disso-
ciation (HCD) with stepped normalized collision energy 
(NCE), 17.5, 35, and 52.5%; spectrum data type, profile; and 
underfill ratio, 1%. Additionally, an inclusion list containing 
m/z values of the suspected adducts was used, although  MS2 
experiments were not limited to these (if idle, pick others). 
TF Xcalibur software version 3.0.63 was used for all data 
handling.
Data processing
Thermo Fisher LC-HRMS/MS RAW files were converted to 
mzXML format using Proteo Wizard (Adusumilli and Mall-
ick 2017). Peak picking was performed using XCMS in an R 
environment (Smith et al. 2006; Team R Core Team); anno-
tation of isotopes, adducts, and artifacts was performed using 
the R package CAMERA (Kuhl et al. 2012). Optimization 
of XCMS parameters was in accordance with a previously 
optimized strategy (Manier et al. 2019b). Peak picking and 
alignment parameters are summarized in Table S1. Accord-
ing to Wehrens et al. (2016), feature abundances with a value 
of zero were replaced by the lowest measured abundance as 
a surrogate LOD and subsequently log10 transformed. A 
batch correction was performed for those features that were 
detected in every QC sample. The corresponding feature 
abundance was corrected using a linear model to extrapo-
late its abundance drift between QC samples (Wehrens et al. 
2016). Additionally, all feature areas were normalized to the 
area of tryptophan-d5, to remove unwanted variation, e.g., 
from pipetting − 80 °C extraction mixtures. Subsequently, a 
corresponding p value was calculated using a one-way analy-
sis of variance (ANOVA) and insignificant features were 
removed from the data set. The data set was filtered keeping 
merely those features with a p-value of < 0.001. Patterns in 
the data set were subsequently investigated using principal 
component discriminant function analysis (PC-DFA) and 
hierarchical clustering. For principal component analysis, 
the features were centered. The subsequent discriminant 
analysis was performed using those principal components 
that fulfilled Kaisers’s criterion, but at least two. The quality 
of the model was assessed using its accuracy of predicting 
group membership, as well as Cohen’s κ after Monte Carlo 
cross-validation. Cohen’s κ was interpreted as proposed by 
Landis and Koch (Landis and Koch 1977). Hierarchical clus-
tering was performed after row scaling, using Euclidean dis-
tances. The names of the features were adopted from XCMS 
using “M” followed by the rounded mass and “T” followed 
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by the retention time in seconds (e.g., “M218T222” as given 
in Table S2 for protonated α-PBP at m/z 218.1538 and a 
retention time of 222 s by reversed-phase chromatography).
Identification of significant features
MS2 spectra were recorded using the above-mentioned PRM 
method to allow identification of significant features. Indi-
vidual spectra were exported after subtracting the baseline 
left and right of the peak. After conversion to mzXML for-
mat using Proteo Wizard, spectra were imported to NIST 
MSSEARCH version 2.3. A library search for identifica-
tion was conducted using the following settings: spectrum 
search type, identity (MS/MS); precursor ion m/z, in spec-
trum; spectrum search options, none; presearch, off; other 
options, none. MS/MS search was conducted using the fol-
lowing settings: precursor tolerance, ± 5 ppm; product ion 
tolerance, ± 10 ppm; ignoring peaks around precursor, ± m/z 
1. The search was conducted by using the following librar-
ies: NIST 14 (nist_msms and nist_msms2 sublibraries) and 
Wiley METLIN Mass Spectral Database. Metabolites of the 
investigated NPS were identified by comparing and inter-
preting their spectra to those of the parent compounds.
Results
Data files in mzXML format and the R script files can be 
found at www.githu b.com/saske ma/hepar gmeta bolom ics. 
The  MS2 spectra of significant features, available as indi-
cated in Table S2–S5 in the supplementary data, can be 
found as well on the above-mentioned repository in mzXML 
format.
Untargeted metabolomics for significant feature 
detection
The results of the ANOVA can be found in Figures S1 and 
S2, scores of the PC-DFA are displayed in Figs. 1 and 2, and 
the corresponding loadings in Figures S3 and S4. The results 
of the hierarchical clustering are displayed in heatmaps in 
Figures S5 and S6. Due to a technical error of the autosam-
pler, one analysis of α-PEP (+ HepaRG) had to be excluded 
from statistical evaluation.
Only few features were found significant after analyses 
of extract 1 (Figure S1 a-d and Figure S2 a-d). For incuba-
tions with α-PBP, four significant features were found after 
reversed-phase chromatography and positive ionization and 
two significant features after normal-phase chromatography 
and positive ionization, as well as one after analysis using 
normal-phase chromatography and negative ionization (Fig-
ures S1 a-d). Analyses using reversed-phase chromatogra-
phy and negative ionization did not lead to any significant 
feature. Concerning extract 1 after α-PEP incubation, any 
analysis using positive ionization led to two significant fea-
tures, while negative ionization did not lead to any signifi-
cant feature. Inspection of the extracted ion chromatograms 
did not imply a high variance within incubation groups, 
but a lack of variance between them, which led to negative 
ANOVA results. Analyses of extract 2 revealed far more 
significant features. For α-PBP, analyses using positive ioni-
zation and reversed-phase chromatography resulted in seven 
significant features and using normal-phase chromatography 
six. Analyses using negative ionization did not expose any 
significant changes. Analyses of cell media using positive 
ionization after incubations with α-PEP led to the discov-
ery of 14 significant features after either using reversed- or 
normal-phase chromatography. Negative ionization analyses 
led to four significant features after reversed-phase chroma-
tography column and three after using normal-phase chro-
matography. After filtering the data set and evaluation using 
PC-DFA, these features showed a consistent clustering of 
incubation groups in each experiment (Figs. 1, 2). Through-
out all score plots, those incubation groups containing the 
corresponding NPS are clearly separated from the group 
“Blank”. Since pooled QC samples were obtained from 
mixing all three incubation groups containing equidistant 
concentrations of the NPS, they contained a concentration 
approximately corresponding to that of the incubation group 
“Low”. This circumstance led to overlapping of both groups 
in most of the displayed score plots.
Concerning the analysis of extract 1, the accuracy of the 
PC-DFA model was 73% for incubations with α-PBP after 
analysis using reversed-phase chromatography and 63% after 
using normal-phase chromatography. Corresponding κ val-
ues were 64% and 51%, respectively. Concerning α-PEP, κ 
values obtained after cross-validation imply good discrimi-
nant properties for features found in cell samples with 84% 
after using reversed-phase chromatography and 71% after 
using normal-phase chromatography.
The quality of the PC-DFA models was best after analy-
sis of extract 2 in positive mode, where at least an accuracy 
of 86% and Cohen’s κ of 82% (category “almost perfect” 
according to Landis and Koch) were achieved. Models of 
cell media experiments (extract 2) of α-PEP that were ana-
lyzed in negative mode and reversed-phase chromatogra-
phy led to a κ value of 67%, which might be categorized 
as “substantial” according to Landis and Koch, while cor-
responding experiments using normal-phase chromatog-
raphy led to a rather low κ value of 56%. The results of 
hierarchical clustering corresponded to those found after 
PC-DFA. Almost all samples from group “Blank” were 
clustered and separated from all other samples containing 
one of the investigated NPS. The Euclidian distance of 
“Blank” group to other samples and the distances between 
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other incubation groups were higher in experiments inves-
tigating extract 2, than in extract 1. Furthermore, groups 
of extract 2 analyzed in negative ionization mode (Figure 
S6 e and f) were less clearly separated than in positive 
mode. Also, the z-scores of the peak intensities indicated 
discrimination of the groups corresponding to hierarchical 
clustering and PC-DFA scores.
Identification of significant features
The results of the identification of significant features are 
summarized in Tables S2-5 in the supplementary data. The 
given level of identification was in accordance with Sum-
ner et al. (2007). Isotopes that were putatively identified 
by CAMERA were not further identified. No  MS2 spectra 
could be recorded for several low abundant features.
Fig. 1  Scores of PC-DFA for α-PBP with the number of principal 
components used for discriminant function analysis, as well as pre-
diction accuracy and Cohen’s κ. a Extract 1 using phenylhexyl col-
umn and positive mode; b Extract 1 using HILIC column and positive 
mode, c Extract 2 using phenylhexyl column and positive mode, d 
Extract 2 using HILIC and positive mode, PC = principal component, 
LD = linear discriminant
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Extract 1
Mainly, the parent compounds and their 13C-isotopes were 
found after α-PBP and α-PEP incubations. Several additional 
features showed significant changes in α-PBP incubations, 
but only the 13C-isotope of N-methylnicotinamide and the 
ammonium adduct of decaethylene glycol could successfully 
be identified. Decaethylene glycol was identified by a partial 
match with hexaethylene glycol. Since the structure of poly-
ethylene glycols is highly repetitive, the polymer length was 
able to be deduced from the protonated parent mass of hexa-
ethylene glycol at m/z 282.1678  (C12H26O7). The structure 
of the corresponding feature M476T250 is thus deducible by 
combination of components of a polyethylene glycol poly-
mer and ammonium as 10 × m/z 44.0261  (C2H4O, repeating 
unit) + m/z 18.0105  (H2O, end group) + m/z 17.0263  (NH4+, 
adduct ion) = m/z 476.3071  (C20H46NO11).
Extract 2
A total of 11 out of 14 features found after α-PBP incubation 
were related to the parent compound. Four features were 
13C-isotopes of the parent compound, while two features 
were related to one metabolite, found after analysis using 
each of the chromatographic methods. Additionally, two fea-
tures were identified to be most likely amino acid adducts 
of α-PBP with glycine and alanine, respectively (Table S3). 
Their  MS2 spectra and the proposed structures are displayed 
in Fig. 3. Since this feature was only found in incubations 
that contained α-PBP and absent in those of group “Blank”, 
a formation of this feature from the NPS itself seemed very 
likely. The fragmentation patterns of these two features indi-
cated a shared basic structure, since both spectra contained 
the same main fragment ions concerning lower masses, 
starting with the fragment ion at m/z 197.1073  (C13H13N2). 
It is also worth noticing that both protonated parent com-
pounds at m/z 271.1446  (C16H19N2O2) for α-PBP glycine 
adduct and at m/z 285.1603  (C17H21N2O2) for α-PBP ala-
nine adduct merely differ by one methyl group in mass and 
deduced sum formula. Additionally, their absolute loadings 
implied that the contribution of these features (M271T249 
and M285T265 in Figure S3 c, M271T423 in Figure S3 
d) to group separation was as high as that of a metabolite 
(M220T217 in Figure S3 c and M220T319 in Figure S3 
d). The amount of metabolites and adducts of α-PBP that 
were identified in cell media samples explained the higher 
discriminating properties of these features, as indicated by 
Cohen’s κ which was 95% for those found after analysis 
using reversed-phase chromatography (Fig. 1c) and 83% for 
those found after analysis using normal-phase chromatogra-
phy, compared to 64% and 51% for extract 1, respectively.
Analysis of samples after α-PEP incubation 2 allowed 
identification of the parent compound, five metabolites, as 
well as one glycine adduct and three more compounds not 
related to α-PEP. Cholesterol sulfate and 25-hydroxycholes-
terol were two of the identified compounds, indicating an 
increased cholesterol metabolism. The proposed structure 
and  MS2 spectra of α-PEP glycine adduct are also displayed 
in Fig. 3. Compared to the spectra of the other adducts, the 
spectrum again contained the same main fragment ions with 
regard to lower masses, starting with the fragment ion at m/z 
197.1073  (C13H13N2), indicating a shared basic structure of all 
three compounds. Additionally, if compared to the spectrum 
of the α-PBP glycine adduct, both spectra share the same main 
fragment ions starting with the second main fragment ion at 
m/z 255.1128  (C15H15N2O2). Considering these obvious simi-
larities and the fact that both glycine adducts merely differ in 
their protonated parent mass by the difference as α-PBP and 
α-PEP do, it is very likely that these features indicate actual 
amino acid adducts. The feature M51T284 in Table S5 could 
not further be investigated due to the mass cutoff of m/z 50 of 
the used mass spectrometer. Nevertheless, concerning its mass 
and retention time, it is likely that this feature is an artifact 
of α-PEP and was thus annotated in Table S5. The feature 
M465T121 did not show any fragmentation after using 10, 20, 
or 40 eV. The only compound in the used mass spectra librar-
ies for identification that had the same monoisotopic mass and 
did not show any fragmentation at the given collision energies 
was cholesterol sulfate. Since higher collision energies than 
40 eV lead to not detecting any signal, it was not possible to 
further confirm its identity. The feature M338T87 in Table S5 
was identified as oleamide.
Incubations for further investigating the formation 
of imines
To confirm the formation of the adducts of the investigated 
NPS with glycine, further incubations were performed to 
confirm the findings described above under simplified condi-
tions. A lower pH in the eluent was used to be able to detect 
glycine. The analysis of the obtained samples revealed that 
both adducts were formed in each incubation containing one 
of the investigated compounds with glycine and Tris buffer or 
cell medium. In incubations with α-PBP and cell media, the 
alanine adduct was found as well. None of the adducts were 
found after incubations using purified water instead of buffer 
solution. Additionally, no adduct of α-PEP and alanine was 
found in incubations with cell medium only.
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Discussion
This study revealed different discriminant properties of 
extract 1 and 2 after PC-DFA. Since it is a multi-class study, 
rather than merely investigating the classification in a blank 
or treatment group, the evaluation of Cohen’s κ is more 
appropriate, due to the fact that it resembles the accuracy of 
the model normalized to the accuracy one would obtain by 
chance (Landis and Koch 1977). Nevertheless, the prediction 
accuracy of the models was also given for completeness.
κ values for analyses extract 1 would be classified as 
“moderate” according to Landis and Koch (Landis and 
Koch 1977), indicating that they have to be interpreted with 
care, while those of extract 2 can be generally classified as 
“almost perfect”.
Those identified compounds that are not related to the 
investigated NPS, give a hint to their effect on physiology of 
the used liver cells. N-Methylnicotinamide is linked to liver 
cirrhosis and might indicate a liver toxic effect of α-PBP 
(Pumpo et al. 2001). The reason why merely its 13C-iso-
tope and not N-nicotinamide itself was found significant 
after ANOVA is likely due to a high within-group variance. 
The interpretation of the role of the two found cholesterol 
metabolites is not possible without speculating, since both 
metabolites are not directly connected to each other. The 
occurrence of polyethylene glycols is rather peculiar. Since 
they are not natural endogenous compounds of cells, it is 
very likely that this feature is the result of contamination 
by a lubricant. During experiments, no lubricant was used 
and it appears to be likely that this contamination happened 
during analysis by the used device. The origin of oleamide 
on the other side is not clearly determinable. Although this 
substance is a naturally occurring endogenous compound, 
McDonald et al. (2008) earlier described that several plas-
ticware contains it as a slip agent. They also demonstrated 
that oleamide is detectable in the water these plasticware 
were rinsed with. Given the fact that the plasticware used 
in this study were among those tested by McDonald et al. 
and the ion chromatograms of oleamide showed high vari-
ability within each incubation group, it is very likely that 
the detected oleamide is not of endogenous origin, but a 
leached slip agent.
It is most likely that the investigated NPS formed imines 
with amino acids during incubations. This formation might 
be achieved after nucleophilic attack of the amine moiety of 
the amino acid at the cathinone carbonyl group. Since incu-
bations using only Tris buffer did not contain any enzymes, 
the ring is likely to be formed during analysis in the ion 
source. It is notable that not every incubation using only 
NPS and amino acid lead to the detection of these adducts. 
The absence of adducts in those incubations using purified 
water might indicate a pH dependency of the formation, 
while the absence of the alanine adduct with α-PEP might be 
due to the fact that it was formed with too low concentrations 
to be detectable in this assay. A summary of the proposed 
mechanism is displayed in Fig. 4. The formation of such an 
adduct also in vivo is likely, since the used concentrations 
of glycine and alanine are similar to those concentrations 
that can be found in human blood (Psychogios et al. 2011).
The metabolism of α-PBP and α-PEP has been thoroughly 
investigated in previous publications using either pHLM 
(Manier et al. 2018, 2019a), primary human hepatocytes 
(Swortwood et al. 2016), or authentic human urine (Mat-
suta et al. 2015). α-PBP was described to be transformed to 
five metabolites, one after reduction of the cathinone car-
bonyl group resulting in a dihydro metabolite and several 
others after oxidation of the pyrrolidine ring, resulting in 
a mono and dihydroxylated metabolite, as well as an oxo 
and a ring-opened hydroxy metabolite. HepaRG did only 
form the dihydro metabolite, one of the main metabolites 
of α-PBP (Manier et al. 2018). Oxidation of the pyrrolidine 
ring was not observed, although, for example, the metabo-
lite found after lactam formation was also described as the 
second main metabolite. This is most probably due to fact 
that the HepaRG cell line was derived from a donor known 
to be a CYP2D6 poor metabolizer (Guillouzo et al. 2007). 
Investigations of the CYP isoforms involved in the metab-
olism of α-PBP revealed that lactam formation of α-PBP 
was only catalyzed by CYP2D6 (Manier et al. 2018). Addi-
tionally, pyrrolidine ring hydroxylation was catalyzed by 
CYP2B6, CYP2C19, and CYP2D6, of which CYP2D6 is 
expressed to a reduced extent due to the cells being derived 
from a poor metabolizing patient and CYP2B6 has a low 
contribution to the hepatic total net clearance of α-PBP. It 
is very likely that the number of metabolites formed after 
oxidation of the pyrrolidine ring was too low to be detected. 
This assumption is supported by the generally low amount 
of CYP2C19 expressed in human liver (Achour et al. 2014). 
The formation of amino acid adducts was not mentioned in 
any of the previously published studies, although the “α-PBP 
impurity (dehydro-) artifact (imido-)” described by Manier 
et al. might represent another in-source artifact of an adduct 
formed after the mechanism proposed in this study.
Concerning the metabolism of α-PEP, only five of the 
nine metabolites described by Manier et al. (2019a) were 
found after incubation of HepaRG cells, although its metab-
olism is catalyzed by a wide variety of CYP enzymes such 
as CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and 
Fig. 2  Scores of PC-DFA for α-PEP with the number of principal 
components used for discriminant function analysis, as well as pre-
diction accuracy and Cohen’s κ. a Extract 1 using phenylhexyl col-
umn and positive mode; b Extract 1 using HILIC column and positive 
mode, c Extract 2 using phenylhexyl column and positive mode, d 
Extract 2 using HILIC and negative mode, e Extract 2 using phenyl-
hexyl column and negative mode, f Extract 2 using HILIC and nega-
tive mode. PC = principal component, LD = linear discriminant
◂
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CYP3A4. Lactam formation, dihydroxylation, hydroxyla-
tion of the side chain, hydroxylation after opening of the 
pyrrolidine ring, and reduction of the cathinone carbonyl 
group were observed. Single pyrrolidine ring hydroxylation, 
dealkylation, and several combinations were not detected. 
Metabolites after N-oxidation, ring opening and formation 
of a carboxylic acid, and dehydrogenation as described by 
Swortwood et al. (2016) were also not detected. Neverthe-
less, alkyl hydroxylation, lactam formation, and reduction 
of the cathinone carbonyl group were described as the main 
metabolic steps of α-PEP and were detected after incuba-
tion with pHS9/pHLM (Manier et al. 2018). Again, adduct 
formation of α-PEP with glycine was not mentioned by any 
of the previously published studies.
Since most metabolites were mainly found in extract 2 
(cell media) and HepaRG cells were described to express 
functional transporter proteins, it is likely that they were 
actively transported (Guillouzo et  al. 2007). Although 
metabolomics studies using pHLM led to higher amounts of 
metabolites of the investigated drugs of abuse, incubations 
Fig. 3  LC–HRMS/MS spectra of amino acid adducts and their predominant fragmentation patterns after incubations with α-PBP or α-PEP. Frag-
ments with accurate mass, calculated elemental formula, and mass error value in parts per million (ppm). The order corresponds to their masses
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using HepaRG cells led to more significant compound 
changes that were not directly linked to the parent com-
pounds. This might give a wider insight into the physiologi-
cal impact on the liver cell metabolome. Depending on the 
aims of the study, it seems more appropriate to use pHLM 
for the investigation of metabolic pathways. If the aims of 
the study are to investigate the direct effect of compounds on 
the physiology of the cells such as hepatotoxicity, it seems 
more appropriate to use HepaRG cells.
Conclusions
Toxicometabolomics of the two NPS α-PBP and α-PEP after 
HepaRG cell line incubation were evaluated by analyzing 
the cells and the cell medium separately. The cross-valida-
tion results of the cell media lead to the conclusion that the 
features found in these experiments had better discriminant 
properties and thus are more suitable as biomarkers for the 
intake of the NPS investigated by this study. Significant 
features found in the cell extracts were mainly the parent 
compounds and their corresponding 13C-isotopes. Signifi-
cant features found in the cell media led to a considerably 
higher amount of significant changes in the metabolome that 
were identified as metabolites of both synthetic cathinones, 
as well as amino acid adducts but also remained unknown 
several features due the lack of reference spectra. They might 
give a wider insight into the physiological changes of the 
cells, since they were not able to be linked to the investigated 
cathinones. So far, only cholesterol sulfate and 25-hydroxy-
cholesterol could be identified to have significantly changed 
in concentrations after incubation of α-PEP, as well as 
N-methylnicotinamide in cell samples after incubation with 
α-PBP. These increased levels of N-methylnicotinamide may 
indicate a potential liver toxic effect of α-PBP. The inves-
tigation of the metabolism of the two synthetic cathinones 
led to fewer metabolites compared to investigations using 
pHLM or primary human hepatocytes, partially owing to 
the fact that HepaRG cells are derived from a CYP2D6-poor 
metabolizing patient. The number of metabolites found in 
α-PBP and α-PEP HepaRG incubated using metabolomics 
techniques may lead to two conclusions. HepaRG cells are 
not appropriate to investigate the metabolism of compounds 
mainly metabolized by CYP2D6. Metabolomics techniques 
are not able to extract all formed metabolites, particularly if 
they are very low abundant. The second conclusion could at 
least be excluded in the present study, as manual inspection 
of the data also did not allow identification of the missed 
metabolites.
The results of the conducted experiments, especially 
those of the incubations of the NPS with amino acids, 
revealed that both NPS formed the highly discriminating 
but unexpected imines with the corresponding amino acid 
during incubations. Their detection underlined the potential 
of toxicometabolomics studies.
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